# US 10,369,198 B2 · Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,369,198 B2
- Document ID: US10369198B2
- Status: Granted
- Kind: B2
- Application number: 14/759,852
- Filed: 2014-01-16
- Published: 2015-12-10
- Granted: 2019-08-06
- Earliest claimed: 2013-01-17
- Assignees: Medizinische Hochschule Hannover
- Applicants: Medizinische Hochschule Hannover
- Inventors: Kai Christoph Wollert; Mortimer Korf-Klingebiel
- Web page: https://patentgrep.com/patent/US10369198B2

## CPC

- A61K 38/18: Growth factors; Growth regulators
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 38/1709: {from mammals}
- A61K 38/177: {Receptors; Cell surface antigens; Cell surface determinants}
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/22: against growth factors {; against growth regulators}
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C12N 2799/022: where the vector is derived from an adenovirus
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to proteins comprising amino acid sequences encoded by nucleic acids derived from the human chromosomal region C19Orf10 termed Factor1 and/or C19Orf63 termed Factor 2 for the use in enhancing proliferation and/or healing and/or inhibiting apoptosis of none-transformed tissue or none-transformed cell or inhibitors thereof. The invention further relates to the use of inhibitors of factor1 and factor 2 for medical use, preferably for use in treating or preventing a disease in which angiogenesis contributes to disease development or progression.

## Claims

### Claim 1

A method for treating myocardial infarction in a subject, comprising: administering to the subject an effective amount of a protein comprising the amino acid sequence according to SEQ ID NO: 1.

### Claim 2 (depends on 1)

The method of claim 1, wherein the protein is administered through the oral, intravenous, intramucosal, intraarterial, intramuscular, subcutaneous, or intracoronary route.

### Claim 3 (depends on 2)

The method of claim 2, wherein the protein is administered before, simultaneously, or after a reperfusion therapy.

### Claim 4 (depends on 3)

The method of claim 3, wherein the administration is through one or more bolus injection(s) and/or infusion(s).

### Claim 5

A method of treating myocardial infarction in a subject, comprising: administering to the subject an effective amount of a pharmaceutical composition comprising a protein comprising the amino acid sequence according to SEQ ID NO: 1.

### Claim 6 (depends on 5)

The method of claim 5, wherein the pharmaceutical composition is administered through the oral, intravenous, intramucosal, intraarterial, intramuscular, subcutaneous, or intracoronary route.

### Claim 7 (depends on 6)

The method of claim 6, wherein the pharmaceutical composition is administered before, simultaneously, or after a reperfusion therapy.

### Claim 8 (depends on 7)

The method of claim 7, wherein the administration is through one or more bolus injection(s) and/or infusion(s).

### Claim 9

A method for treating a disease or disorder excluding myocardial infarction, comprising administering to a subject in need thereof an amount effective to treat the disease of a protein comprising the amino acid sequence according to SEQ ID NO: 1;
wherein the disease or disorder is a heart-related disease selected from the group consisting of inherited cardiomyopathy, cardiomyopathy caused by spontaneous mutations, acquired cardiomyopathy, cardiomyopathy caused by infection of the myocardium, hypertensive heart disease caused by pulmonary arterial hypertension, arterial hypertension, diseases of the heart valves, ischemia reperfusion injury, inflammation, infection, trauma, mechanical overload, angina pectoris, and heart failure.